Checkpoint inhibitor treatment, including blockade of the PD-1 receptor, has shown limited efficacy in the murine B16F10 melanoma model, despite strong expression of the ligand PD-L1 on the tumor cells (41) — a feature attributed to low tumor infiltration by effector CD8+ T cells (44, 45). The gene discussed is CD8A; the disease is melanoma.